Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/5/2008

pacity for future potential orders of pegloticase.

Selling, general and administrative expenses for the first nine months of 2008 were $27.3 million, an increase of $6.0 million or 28%. The increase is primarily due to higher legal costs resulting from patent infringement litigation and loss contingencies for the settlement of two legal proceedings, higher share-based compensation expense substantially due to an increase in the quantity of certain performance-based and service-based restricted stock awards and an increase in pre-launch pegloticase marketing and marketing research expenses as we prepare for the potential commercial launch of the product. Partially offsetting the above increases was a decrease in accounting and tax related professional fees.

Investment income for the first nine months of 2008 was $1.7 million, a decrease of $5.1 million or 75%. This decrease was primarily attributable to a decrease in dividend and interest income on lower cash, cash equivalent and investment balances and lower yields earned on these investments.

CONFERENCE CALL

Savient will host a live web cast to review third quarter 2008 results on November 6, 2008 at 10:00 a.m. EST. Both the live and archived web cast can be accessed from the Investor Relations page of Savient's website at http://www.savient.com. A digital recording of the web cast will be available within one hour following the conclusion of the call and will be available for 14 days. To access the recording, use the Dial-In Number and the Conference ID listed below.

Dial: (800) 642-1687 (domestic) or (706) 645-9291 (international)

Conf ID: 67897749

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Savient Submits Biologics License Application (BLA) for pegloticase
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
4. Onyx Pharmaceuticals to Present at the 2008 Credit Suisse Health Care Conference
5. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
6. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
7. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
8. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
9. VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
10. OncoMed Pharmaceuticals Completes Series B Financing
11. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Array BioPharma Inc. (NASDAQ: ... definitive agreement with Novartis Pharma AG to acquire worldwide ... Phase 3 development.  This agreement is conditional on the closing ... on April 22, 2014, which are expected to close in ...
(Date:1/22/2015)... GEA Niro Soavi the leader in ... the PandaPLUS 2000, which is ideal for new applications ... cell disruption . This compact laboratory homogenizer is the ... food, food additives and ingredients as well as for ...
(Date:1/22/2015)... OH (PRWEB) January 22, 2015 Crystal Diagnostics ... today that it has received AOAC-PTM Certifications for the six ... O121, and O145; collectively referred to as STEC or the ... 1 colony forming unit (cfu) per 325 g of raw ...
(Date:1/22/2015)... January 22, 2015 Selexis SA, a ... Research Cell Banks (RCBs) used for drug discovery to ... Banks will include Next-Generation Sequencing (NGS) data ... de-risks biologic manufacturing by ensuring the integrity of the ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... Oxford Biomedica,s,second attempt to dismiss Bavarian Nordic,s patent ... denying infringement, Oxford Biomedica,made yet another attempt to dismiss ... still evaluated in clinical trials. The court ruled,against Oxford ... the,substance of the patents. , ...
... 8 Sinovac Biotech Ltd. (Amex: SVA ), ... it will host a conference call on Friday, May 15, ... quarter financial results for the period ended March 31, 2009 ... conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). ...
... (Nasdaq: NVAX) today announced financial results for ... of $8.3 million, or $0.12 per share, for the first quarter ... $0.13 per share, for the first quarter of 2008. The ... of 2009 and ended the quarter with $25.6 million in cash ...
Cached Biology Technology:The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results 2Novavax Reports First Quarter 2009 Financial Results 2Novavax Reports First Quarter 2009 Financial Results 3Novavax Reports First Quarter 2009 Financial Results 4Novavax Reports First Quarter 2009 Financial Results 5Novavax Reports First Quarter 2009 Financial Results 6Novavax Reports First Quarter 2009 Financial Results 7Novavax Reports First Quarter 2009 Financial Results 8
(Date:1/22/2015)... and POINT ROBERTS, Washington , January 20, ... leading sectors including technology and tech stocks, releases video from ... master pickpocket and security consultant Apollo Robbins . ... talks about the Wocket™ biometric smart wallet, a product of ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Global Wearable Technologies Market ... Share, Overview, Trends and Forecast 2014-2020" report ... Technologies are smart devices that can be worn ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  Since its launch in December ... people to eliminate the pain of trying to remember their ... own biometrics fused to their smartphones. To assist people who ... , the company that created 1U and focuses on redefining ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... Inducing cellular immunity as a means to protect against ... the Trudeau Institute.,Researchers here have recently identified two important ... allow us to pre-position our own virus-fighting T cells ... In laboratories around the world, researchers are working diligently ...
... How do children reason about the natural world? How ... animals? For decades, the consensus was that as ... adopt an "anthropocentric" stance, favoring humans over non-human animals ... But Northwestern University researchers have taken another ...
... Mark Bolland, Senior Research Fellow at the Department of Medicine, ... Director, Health Economics and Outcomes Research at Amaris, UK, have ... Award. The award, an honorarium of 2,000 ... by young researchers (first authors under the age of 40) ...
Cached Biology News:Directing immune traffic -- signposts to the lung 2Animals talk, sing and act like humans? 2
... Aph-1a (Aph-1aL,S Loop 92-115), O2F1 Affinity ... a multiprotein complex consisting of presenilin, ... proteins are necessary for full proteolytic ... cleavage of a number of integral ...
... Biochem/physiol Actions: Glutathione-S-transferases (GSTs) are a group ... many xenobiotics in mammals. The enzymes ... thiol group of the glutathione to electrophilic ... mutagenic, carcinogenic, and toxic effects of the ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Amodiaquine...
Biology Products: